A Study to Evaluate ALN-2232 in Participants With Obesity
A Phase 1/2, Randomized, Double-blind, Placebo-controlled, Study of the Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of ALN-2232 as Monotherapy and Co-initiated With Tirzepatide in Adult Participants With Obesity
Alnylam Pharmaceuticals
156 participants
Mar 2, 2026
INTERVENTIONAL
Conditions
Summary
The purpose of this study is to: * evaluate the safety, tolerability, efficacy, pharmacokinetics (PK), and pharmacodynamics (PD) of single ascending doses of ALN-2232 in patients with obesity * evaluate the safety, tolerability, efficacy, PK, and PD of multiple doses of ALN-2232 in patients with obesity * evaluate the safety, tolerability, efficacy, PK, and PD of multiple doses of ALN-2232 co-initiated with tirzepatide in patients with obesity
Eligibility
Inclusion Criteria3
- All Parts:
- Has a body mass index (BMI) of ≥30 kg/m\^2 and <40 kg/m\^2
- Has a hemoglobin A1c (HbA1c) <6.5%
Exclusion Criteria3
- All Parts:
- Has any clinically significant concomitant disease, medical condition, or abnormal laboratory finding that could compromise participant safety or confound interpretation of study results
- Receiving therapies for chronic weight management or antidiabetic medications
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
ALN-2232 will be administered subcutaneously (SC)
Placebo will be administered SC
Tirzepatide will be administered SC
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07463846